Tangram Therapeutics submitted a clinical trial application to the UK’s MHRA to initiate a Phase I/II study of TGM‑312 for metabolic dysfunction‑associated steatohepatitis (MASH). The CTA covers first‑in‑human dosing to evaluate safety, pharmacology and preliminary efficacy in a disease with high unmet need. TGM‑312 targets pathways implicated in hepatic inflammation and metabolic dysfunction; Tangram will use the CTA to enroll dose‑escalation cohorts and early proof‑of‑concept patients. The company emphasized clinical development in the U.K. regulatory environment to leverage streamlined trial conduct and investigator networks experienced in NASH/MASH trials. This move places Tangram among a growing cohort pursuing therapeutics for fatty‑liver disease beyond traditional metabolic targets, and investors will track early biomarker readouts and tolerability as the program advances.